Understanding how GSTP1 affects breast cancer and its treatment
Investigating GSTP1 as a novel regulator of the cysteine redoxome in breast cancer and maker of vulnerability to redox-based therapy
This study is looking at how a specific enzyme called GSTP1 affects breast cancer cells and their response to treatment, with the hope of finding new ways to make treatments more effective for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10753588 on NIH RePORTER |
What this research studies
This research investigates the role of the enzyme GSTP1 in breast cancer, particularly how its silencing affects cancer cell behavior and treatment responses. By examining cancer cell lines and patient tumors, the study aims to uncover how reduced GSTP1 expression can create vulnerabilities in breast cancer cells, potentially leading to new therapeutic strategies. The researchers will explore the molecular changes that occur when GSTP1 is silenced, focusing on how this impacts redox signaling and cancer transformation. Patients may benefit from insights that could lead to more effective treatments targeting GSTP1-related pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer, particularly those with luminal or Her2 positive subtypes.
Not a fit: Patients with breast cancer types that do not involve GSTP1 silencing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for breast cancer patients by identifying vulnerabilities in cancer cells.
How similar studies have performed: Previous research has shown promising results in targeting metabolic vulnerabilities in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Held, Jason M. — Washington University
- Study coordinator: Held, Jason M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.